Omeros corporation reports interim data with alternative pathway inhibitor oms906 as monotherapy in patients with paroxysmal nocturnal hemoglobinuria

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced positive results from a pre-specified interim analysis of its ongoing phase 1b clinical trial of oms906, the company's lead masp-3 inhibitor, in complement-inhibitor-naÏve adults with paroxysmal nocturnal hemoglobinuria (pnh), a rare and life-threatening hemolytic blood disorder. statistically significant and clinically meaningful improvements were observed in all measured markers of hemolysis, including hemoglobin (hgb.
OMER Ratings Summary
OMER Quant Ranking